{"prompt": "['MK-7902', 'PAGE 8', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Statistical Methods for', 'The primary hypotheses will be evaluated by comparing pembrolizumab +', 'Key Safety Analyses', 'lenvatinib to pembrolizumab + placebo in PFS and os using a stratified log-rank', 'test and in ORR using the stratified Miettinen and Nurminen method [Miettinen,', 'O. 1985]. The HR will be estimated using a stratified Cox regression model. Event', 'rates over time will be estimated within each treatment group using the Kaplan-', 'Meier method. The difference in ORR will be estimated using the stratified', 'Miettinen and Nurminen method with strata weighting by sample size.', 'Interim Analyses', 'One interim analysis and one final analysis are planned for this study. Results will', 'be reviewed by an external Data Monitoring Committee (DMC). Details are', 'provided in Section 9.7.', 'Interim analysis (IA): to be performed after ~416 PFS events are observed', 'and', '~8.8 months after last participant randomized', 'Primary purpose: final PFS analysis and interim OS analysis', 'Final analysis: to be performed after ~388 deaths are observed and - -18.5', 'months after last participant randomized', 'Primary purpose: final OS analysis', 'Note that for the IA and the FA, if the events accrue slower than expected such', 'that the targeted number of events cannot be reached in the anticipated timeframe,', 'the Sponsor may conduct the analysis with an additional 2 months and 7 months of', 'follow-up for the IA and FA respectively, or the specified number of events is', 'observed, whichever occurs first.', 'Multiplicity', 'The overall Type I error rate over the multiple endpoints will be strongly', 'controlled at 2.5% (1-sided). A 0.55% (1-sided) will be initially allocated to test', 'PFS and 1.95% (1-sided) allocated to test OS. The graphical approach of Maurer', 'and Bretz [Maurer, W., et al 2011] will be applied to reallocate a among the', 'hypotheses for ORR, PFS, and OS. Lan-DeMets [Lan, K. K. G. and DeMets, D. L.', \"1983] and O'Brien-Fleming [O'Brien, P. C. and Fleming, T. R. 1979] group\", 'sequential methods will be used to allocate a among the interim and final analysis', 'for the os endpoint.', 'Sample Size and Power', 'The planned sample size is approximately 620 participants. For PFS, based on 416', 'events, the study has 86.5% power to detect a HR of 0.7 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at =0.55% (1-sided). For OS, based on', '388 events, the study has 90% power to detect a HR of 0.71 (pembrolizumab +', 'lenvatinib vs pembrolizumab + placebo) at =1.95% (1-sided).', 'China Extension Study', 'China participants randomized during the global study phase will be included in all', 'global study analyses (efficacy and safety). China participants randomized during', 'the China extension phase will be excluded from all global study analyses. China', 'participants randomized during global and extension phases will both be included', 'in the China-specific analyses.', '3.2. Responsibility for Analyses/In-house Blinding', 'The statistical analysis of the data obtained from this study will be the responsibility of the', 'Clinical Biostatistics department of the Sponsor.', 'This study will be conducted as a double-blind study under in-house blinding procedures. The', 'official, final database will not be unblinded until medical/scientific review has been performed,', 'protocol deviations have been identified, and data have been declared final and complete.', 'Confidential']['MK-7902', 'PAGE 9', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'The Sponsor will generate the randomized allocation schedule(s) for study intervention', 'assignment.', 'Blinding issues related to the planned interim analyses are described in Section 3.7.', '3.3. Hypotheses/Estimation', 'Objectives and hypotheses of the study are stated in Section 3 of the study protocol.', '3.4. Analysis Enppoints', 'Efficacy and safety endpoints that will be evaluated for within- and between-treatment', 'differences are listed below.', '3.4.1.', 'Efficacy Enppoints', '3.4.1.1.', 'Primary Enppoints', 'PFS: the time from randomization to the first documented PD per RECIST 1.1, adjusted to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, based on', 'BICR or death due to any cause, whichever occurs first. See Section 9.6.1 for the definition of', 'censoring.', 'OS: the time from randomization to death due to any cause.', '3.4.1.2.', 'Secondary Enppoints', 'OR: a confirmed CR or PR per RECIST 1.1, adjusted to follow a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ, based on BICR.', '3.4.1.3.', 'Exploratory Endpoints', 'DOR: the time from the earliest date of qualifying response until earliest date of PD or death', 'from any cause, whichever comes first.', '3.4.2.', 'Safety Enppoints', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, SAEs, fatal AEs, laboratory tests, and vital signs. Furthermore, specific events will be', 'collected and designated as ECIs as described in Section 8.4.7 of the study protocol.', '3.4.3.', 'Patient-reported Outcome Endpoints', 'Secondary', 'Mean change from baseline in EORTO QLQ-C30 global health status/QoL (items 29-30),', 'physical functioning (items 1-5), and dyspnea scores (item 8), and EORTC QLQ-LC13', 'cough (item 31) and chest pain (item 40) scores.', 'Confidential']\n\n###\n\n", "completion": "END"}